A retrospective cohort study published in Diabetes Research and Clinical Practice reports that adults with type 2 diabetes taking tirzepatide had lower recorded rates of periodontitis, tooth extraction and oral infection than matched patients taking GLP-1 receptor agonists. The authors are explicit that this is an association drawn from electronic health records, not a trial result.

Tirzepatide (sold as Mounjaro and Zepbound) is a dual GIP and GLP-1 receptor agonist, while the comparator group covers the older single-target GLP-1 receptor agonists such as semaglutide. Both classes are used widely in type 2 diabetes and obesity, and dental outcomes are not something either was designed around, which is part of what makes the question interesting.

How the study was built

The researchers used the TriNetX Global Collaborative Network to identify adults with type 2 diabetes starting either drug between May 2022 and May 2025, then applied 1:1 propensity score matching on baseline characteristics from the preceding year. After matching, each cohort contained 97,993 patients, and Cox models estimated hazard ratios over one year of follow-up.

Key results

Tirzepatide was associated with lower risks of periodontitis (HR 0.70, 95% CI 0.57 to 0.86), tooth extraction (0.89, 0.84 to 0.94), peri-implant complications (0.61, 0.52 to 0.70), periodontal procedures (0.89, 0.85 to 0.94), and oral or maxillofacial infections (0.70, 0.62 to 0.79). The composite oral and periodontal outcome came in at HR 0.87 (0.84 to 0.91), and all-cause mortality at 0.69 (0.59 to 0.80).

That mortality figure is worth pausing on, because a one-year all-cause mortality difference of that size in a matched EHR comparison usually signals residual confounding somewhere rather than a clean drug effect. The authors ran subgroup, extended follow-up, active-comparator, composite-outcome and E-value analyses, and report the direction of the findings held across them.

Limitations

The study is retrospective and built on routinely recorded EHR data, so an outcome only exists if a clinician coded it, and the authors note the recorded event rates were low. Propensity matching cannot account for unmeasured differences between the two groups, and the authors say the associations require confirmation in prospective studies with systematic dental assessments.

Bottom line

This is a very large matched cohort pointing consistently in one direction on a question nobody was really asking, which makes it a reasonable prompt for a proper prospective study. Until someone runs one with actual dental examinations rather than billing codes, the finding stays an association.